Abivax’s lead candidate, ABX464, is gearing up to launch a Phase III program this year in about 1,400 patients with moderate-to-severe ulcerative colitis (UC). The company has held an end-of-Phase II meeting with the FDA and received scientific feedback from the European Medicines Agency. Both agencies supported ABX464 advancing into Phase III. Abivax’s treatments are designed to modulate the body’s inflammation and immunological pathways . . .